Founded in 2017, RubrYc Therapeutics, Inc. emerged as a biotherapeutic discovery partner of immunomics leader HealthTell, Inc. The Company has exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidates that are optimized for clinical development.
|
Date |
Amount |
Type |
Investors |
Valuation |
|---|---|---|---|---|
| 04/11/18 | $10,000,000 | Series A |
Paladin Capital Group Third Point Ventures  Vital Venture Capital | undisclosed |
